Highly Variant DNA Methylation in Normal Tissues Identifies a Distinct Subclass of Cancer Patients
Overview
Affiliations
The "CpG Island Methylator Phenotype" (CIMP) has been found to be a useful concept in stratifying several types of human cancer into molecularly and clinically distinguishable subgroups. We have identified an additional epigenetic stratification category, the "Outlier Methylation Phenotype" (OMP). Whereas CIMP is defined on the basis of hyper-methylation in tumor genomes, OMP is defined on the basis of highly variant (either or both hyper- and hypo-methylation) methylation at many sites in normal tissues. OMP was identified and defined, originally, as being more common among low birth weight individuals conceived in vitro but we have also identified OMP individuals among colon cancer patients profiled by us, as well as multiple types of cancer patients in the TCGA database. The cause(s) of OMP are unknown, as is whether these individuals identify a clinically useful subgroup of patients, but both the causes of, and potential consequences to, this epigenetically distinct group are of great interest.
Yates J, Schaufelberger H, Steinacher R, Schar P, Truninger K, Boeva V J Natl Cancer Inst. 2024; 116(6):974-982.
PMID: 38273663 PMC: 11160500. DOI: 10.1093/jnci/djae016.
Liu F, Liu J, Shi X, Hu X, Wei L, Huo B Sci Rep. 2023; 13(1):12494.
PMID: 37528145 PMC: 10394090. DOI: 10.1038/s41598-023-39784-1.
Disrupted methylation patterns at birth persist in early childhood: a prospective cohort analysis.
Dolinko A, Schultz B, Ghosh J, Kalliora C, Mainigi M, Coutifaris C Clin Epigenetics. 2022; 14(1):129.
PMID: 36243864 PMC: 9568969. DOI: 10.1186/s13148-022-01348-x.
Ghosh J, Schultz B, Chan J, Wultsch C, Singh R, Shureiqi I Cancer Prev Res (Phila). 2022; 15(11):755-766.
PMID: 36219239 PMC: 9623234. DOI: 10.1158/1940-6207.CAPR-22-0258.
Soares-Lima S, Mehanna H, Camuzi D, de Souza-Santos P, de Almeida Simao T, Nicolau-Neto P Cancers (Basel). 2021; 13(12).
PMID: 34208581 PMC: 8234055. DOI: 10.3390/cancers13123014.